Key Aspects Regarding the Introduction and Prioritisation of COVID-19 Vaccination in the EU/EEA and the UK   [open pdf - 0B]

From the Summary: "This document provides an overview of the key aspects related to the initial phases following the introduction of one or more COVID-19 [coronavirus disease 2019] vaccines in the European Union and European Economic Area (EU/EEA) and the United Kingdom (UK). The aim is to support but not define EU policy on COVID-19 vaccination. [...] COVID-19, caused by the virus SARS-CoV-2 [severe acute respiratory syndrome coronavirus 2], is a new disease, and no vaccine is yet available for it, posing great challenges to the early development of national vaccination strategies. Patterns of exposure to SARS-CoV-2, as well as the incidence, burden and geographical distribution of COVID-19, will influence choices about vaccine deployment. There is currently a lack of certainty and knowledge about the characteristics of COVID-19 vaccines that could become available in the EU/EEA and the UK, as well as remaining gaps in the scientific knowledge of the virus and the disease. Vaccination plans and strategies will therefore need to be adapted as more information becomes available. Once vaccines against COVID-19 are available, their supply is likely to be limited, at least initially. Supply capacity, both initially and over time, will thus determine vaccine usage and delivery prioritisation. Deployment will need to be adjusted accordingly to promptly optimise vaccine allocation and ensure vaccine availability to those most in need."

2020 European Centre for Disease Prevention and Control
Retrieved From:
European Centre for Disease Prevention and Control: https://www.ecdc.europa.eu/
Media Type:
Help with citations